The financial print missed the market's bar. Revenue was only $1.7 million, versus a published consensus near $4.1 million, with no license revenue in the quarter; the filing does not provide EPS, so an EPS comparison cannot be made.
| Metric | Q2 2026 | Q2 2025 / reference | Market expectation |
|---|---|---|---|
| Total revenue | $1.7M (Financial Results) | $2.7M (Income Statement) | ~$4.1M consensus |
| R&D expense | $85.3M (Financial Results) | $108.8M (Income Statement) | — |
| G&A expense | $23.4M (Financial Results) | $34.5M (Income Statement) | — |
| Lonigutamab impairment | $41.8M (Financial Results) | $0 (Income Statement) | — |
| Net loss | $142.2M (Financial Results) | $59.3M net income (Income Statement) | — |
| Cash, cash equivalents and marketable securities | $502.3M (Financial Guidance) | — | Runway into Q4 2027 |
The psoriasis dataset is the main offset, but not a clean surprise. ONWARD3 showed 75% of patients reaching PASI 90 and 54% reaching complete skin clearance after up to 48 weeks in 773 patients, with a safety profile described as consistent with earlier trials (ONWARD3). That supports the commercial and regulatory case, but the company had already reported positive pivotal Phase 3 ONWARD1 and ONWARD2 topline results in January 2026, making this more confirmation and durability detail than a wholly new thesis reset (ONWARD3).
The pipeline was narrowed, not simply expanded. Alumis remains on track for a psoriasis NDA submission in Q4 2026 and expects potentially pivotal SLE data in Q3 2026 (Anticipated 2026 Milestones). At the same time, it is exploring strategic alternatives for lonigutamab and recorded a $41.8 million impairment tied to that program (TYK2 Franchise and Pipeline Update; Financial Results). That write-down removes value from a non-core asset and signals sharper capital discipline, but also confirms the pipeline is becoming more dependent on envudeucitinib.
Cash buys time, not validation. The $502.3 million liquidity position and stated runway into Q4 2027 reduce near-term financing pressure (Financial Guidance). Net, however, the revenue miss and lonigutamab impairment outweigh the supportive psoriasis durability data because the clinical milestones were largely anticipated and the filing did not introduce a new financial catalyst.
Read the original 8-K on SEC EDGAR ↗